191 related articles for article (PubMed ID: 27764790)
61. Ovarian cancer: genomic analysis.
Wei W; Dizon D; Vathipadiekal V; Birrer MJ
Ann Oncol; 2013 Dec; 24 Suppl 10(Suppl 10):x7-15. PubMed ID: 24265410
[TBL] [Abstract][Full Text] [Related]
62. Targeted Therapy in Ovarian Cancer. A Comprehensive Systematic Review of Literature.
Diab Y; Muallem MZ
Anticancer Res; 2017 Jun; 37(6):2809-2815. PubMed ID: 28551615
[TBL] [Abstract][Full Text] [Related]
63. Ovarian Cancer Genetics and Implications for Imaging and Therapy.
Elsherif SB; Faria SC; Lall C; Iyer R; Bhosale PR
J Comput Assist Tomogr; 2019; 43(6):835-845. PubMed ID: 31738206
[TBL] [Abstract][Full Text] [Related]
64. Fear of Cancer Recurrence in an Era of Personalized Medicine.
Thewes B; Husson O; Poort H; Custers JAE; Butow PN; McLachlan SA; Prins JB
J Clin Oncol; 2017 Oct; 35(29):3275-3278. PubMed ID: 28723231
[No Abstract] [Full Text] [Related]
65. [Position of targeted therapy in ovarian cancer management].
Majirský M; Kubecová M; Kindlová E; Tikovský K
Ceska Gynekol; 2013 Aug; 78(4):347-50. PubMed ID: 24040982
[TBL] [Abstract][Full Text] [Related]
66. Drug delivery systems for ovarian cancer treatment: a systematic review and meta-analysis of animal studies.
Raavé R; de Vries RB; Massuger LF; van Kuppevelt TH; Daamen WF
PeerJ; 2015; 3():e1489. PubMed ID: 26713240
[TBL] [Abstract][Full Text] [Related]
67. Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review).
Sisman Y; Schnack T; Høgdall E; Høgdall C
Mol Clin Oncol; 2022 Feb; 16(2):29. PubMed ID: 34987799
[TBL] [Abstract][Full Text] [Related]
68. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.
Mantia-Smaldone GM; Edwards RP; Vlad AM
Cancer Manag Res; 2011; 3():25-38. PubMed ID: 21734812
[TBL] [Abstract][Full Text] [Related]
69. Biomarkers and the 'target therapies' in oncology, research and business.
Nicolini A
Biomark Med; 2017 Mar; 11(3):217-219. PubMed ID: 28240099
[No Abstract] [Full Text] [Related]
70. Anti-angiogenetic agents against tumor types and cardiovascular risk.
Economopoulou P; Kotsantis I; Psyrri A
Hellenic J Cardiol; 2017; 58(3):220-222. PubMed ID: 28844944
[No Abstract] [Full Text] [Related]
71. Putting the "Person" in Personalized Cancer Medicine: A Systematic Review of Psychological Aspects of Targeted Therapy.
McFarland DC; Hamilton JG; Fox R; Holland J
Pers Med Oncol; 2014 Dec; 3(8):438-447. PubMed ID: 32457974
[No Abstract] [Full Text] [Related]
72. Bevacizumab in ovarian cancer: A critical review of phase III studies.
Rossi L; Verrico M; Zaccarelli E; Papa A; Colonna M; Strudel M; Vici P; Bianco V; Tomao F
Oncotarget; 2017 Feb; 8(7):12389-12405. PubMed ID: 27852039
[TBL] [Abstract][Full Text] [Related]
73. CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo.
Qi ZY; Wang F; Yue YY; Guo XW; Guo RM; Li HL; Xu YY
J Ovarian Res; 2019 Nov; 12(1):118. PubMed ID: 31783885
[TBL] [Abstract][Full Text] [Related]
74. High Expression Levels of AGGF1 and MFAP4 Predict Primary Platinum-Based Chemoresistance and are Associated with Adverse Prognosis in Patients with Serous Ovarian Cancer.
Zhao H; Sun Q; Li L; Zhou J; Zhang C; Hu T; Zhou X; Zhang L; Wang B; Li B; Zhu T; Li H
J Cancer; 2019; 10(2):397-407. PubMed ID: 30719133
[TBL] [Abstract][Full Text] [Related]
75. Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.
Zhang M; Zhang M; Wang J; Cai Q; Zhao R; Yu Y; Tai H; Zhang X; Xu C
Drug Deliv; 2018 Nov; 25(1):995-1003. PubMed ID: 29667478
[TBL] [Abstract][Full Text] [Related]
76. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.
Botta C; Ciliberto D; Rossi M; Staropoli N; Cucè M; Galeano T; Tagliaferri P; Tassone P
Blood Adv; 2017 Feb; 1(7):455-466. PubMed ID: 29296961
[TBL] [Abstract][Full Text] [Related]
77. ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.
Saglam O; Xiong Y; Marchion DC; Strosberg C; Wenham RM; Johnson JJ; Saeed-Vafa D; Cubitt C; Hakam A; Magliocco AM
Cancer Control; 2017 Jan; 24(1):89-95. PubMed ID: 28178720
[TBL] [Abstract][Full Text] [Related]
78. Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation.
Staropoli N; Ciliberto D; Chiellino S; Caglioti F; Giudice TD; Gualtieri S; Salvino A; Strangio A; Botta C; Pignata S; Tassone P; Tagliaferri P
Oncotarget; 2016 Dec; 7(50):82741-82756. PubMed ID: 27764790
[TBL] [Abstract][Full Text] [Related]
79. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
Lawrie TA; Rabbie R; Thoma C; Morrison J
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
[TBL] [Abstract][Full Text] [Related]
80. The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
Staropoli N; Ciliberto D; Del Giudice T; Iuliano E; Cucè M; Grillone F; Salvino A; Barbieri V; Russo A; Tassone P; Tagliaferri P
Crit Rev Oncol Hematol; 2018 Nov; 131():83-89. PubMed ID: 30293710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
